Altimmune, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | $1.7M | $184.9M | $179.9M |
| Jun 2022 | $1.5M | $194.5M | $135.9M |
| Sep 2022 | $4.5M | $205.0M | $127.5M |
| Dec 2022 | $4.6M | $185.3M | $111.1M |
| Mar 2023 | $4.4M | $167.7M | $104.7M |
| Jun 2023 | $4.2M | $167.7M | $102.4M |
| Sep 2023 | $4.3M | $150.4M | $86.9M |
| Dec 2023 | — | $194.1M | $135.1M |
| Mar 2024 | — | $172.9M | $79.0M |
| Jun 2024 | — | $152.5M | $57.1M |
| Sep 2024 | — | $133.4M | $31.5M |
| Dec 2024 | — | $123.5M | $36.9M |
| Mar 2025 | — | $142.2M | $49.1M |
| Jun 2025 | $14.3M | $161.4M | $183.1M |
| Sep 2025 | $14.4M | $185.6M | $61.2M |
| Dec 2025 | $34.3M | $224.9M | $43.8M |
| Mar 2026 | $34.5M | $284.0M | $97.6M |
| Jun 2026 | $34.7M | $474.2M | $63.0M |